Germline EGFR Mutations and Familial Lung Cancer.

Autor: Oxnard GR; Dana-Farber Cancer Institute, Boston, MA., Chen R; Dana-Farber Cancer Institute, Boston, MA., Pharr JC; Dana-Farber Cancer Institute, Boston, MA., Koeller DR; Dana-Farber Cancer Institute, Boston, MA., Bertram AA; Dana-Farber Cancer Institute, Boston, MA., Dahlberg SE; Dana-Farber Cancer Institute, Boston, MA., Rainville I; Dana-Farber Cancer Institute, Boston, MA., Shane-Carson K; Ohio State University Medical Center, Columbus, OH., Taylor KA; Vanderbilt-Ingram Cancer Center, Nashville, TN., Sable-Hunt A; Addario Lung Cancer Medical Institute (ALCMI), San Carlos, CA., Sholl LM; Brigham and Women's Hospital, Boston, MA., Teerlink CC; Huntsman Cancer Center, Salt Lake City, UT., Thomas A; Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT., Cannon-Albright LA; Huntsman Cancer Center, Salt Lake City, UT., Fay AP; PUCRS School of Medicine, Porto Alegre, Brazil., Ashton-Prolla P; PUCRS School of Medicine, Porto Alegre, Brazil., Yang H; Columbia University Medical Center, New York, NY., Salvatore MM; Columbia University Medical Center, New York, NY., Addario BJ; Addario Lung Cancer Medical Institute (ALCMI), San Carlos, CA., Jänne PA; Dana-Farber Cancer Institute, Boston, MA., Carbone DP; Ohio State University Medical Center, Columbus, OH., Wiesner GL; Vanderbilt-Ingram Cancer Center, Nashville, TN., Garber JE; Dana-Farber Cancer Institute, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 01; Vol. 41 (34), pp. 5274-5284. Date of Electronic Publication: 2023 Oct 23.